A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses
Proceedings of the National Academy of Sciences · 15.04.2025 · 122 (15)
DOI: 10.1073/pnas.2424889122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 07.04.2025. Verfasst von Xin Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Zanamivir, Antiviral Agents, Influenza, Human. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH (NIH).
Abstract (Originalsprache)
Influenza remains a significant public health threat. Both monoclonal antibodies and small-molecule inhibitors can target the influenza surface glycoproteins hemagglutinin (HA) or neuraminidase (NA) for prevention and treatment of influenza. Here, we combine the strengths of anti-influenza antibodies and small molecules by site-specific conjugation of the NA inhibitor zanamivir to MEDI8852, an HA-specific fully human monoclonal antibody. MEDI8852 targets the conserved stem region of HA and inhibits HA-mediated fusion of the viral and host cell membranes. Elimination of virus-infected cells involves Fcγ receptor–mediated effector functions. The efficacy of MEDI8852 is limited to influenza A viruses. Zanamivir, on the other hand, binds to the active site of NA in both influenza A and B viruses to inhibit NA activity and virus release. However, because of its small size, zanamivir has a short half-life and requires repeated dosing at high concentrations. We produced a MEDI8852–zanamivir antibody–drug conjugate (ADC) that engages Fc-mediated effector functions and benefits from neonatal Fc receptor (FcRn)-mediated recycling. The MEDI8852–zanamivir conjugate extends the circulatory half-life of zanamivir, targets both influenza HA and NA, and shows enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to MEDI8852 alone. The MEDI8852–zanamivir conjugate protected mice from a lethal (10 × LD 50 ) challenge with influenza A and B viruses at a dose similar to that required for broadly neutralizing anti-NA antibodies, with the added advantage of simultaneously targeting NA (influenza A and B) and HA (influenza A).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
ORCID-Profile: Hidde L Ploegh
Förderung
- NIAID NIH HHS
- HHS | NIH (NIH)
Zitieren
APA
Liu, X., Balligand, T., Le Gall, C., & Ploegh, H. L. (2025). A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses. Proceedings of the National Academy of Sciences, 122(15). https://doi.org/10.1073/pnas.2424889122
Vancouver
Liu X, Balligand T, Le Gall C, Ploegh HL. A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses. Proceedings of the National Academy of Sciences. 2025;122(15). doi:10.1073/pnas.2424889122
BibTeX
@article{Liu2025,
author = {Liu, Xin and Balligand, Thomas and Le Gall, Camille and Ploegh, Hidde L},
title = {A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {15},
doi = {10.1073/pnas.2424889122}
}
EUVIMED